According to a statement released on Wednesday, this makes Biovac the first company in
Biovac is set to immediately commence technical transfer activities, which include on-site development and equipment installation activities.
In addition, the company, which is partly owned by the South African government, will obtain drug substances from facilities in
At full operational capacity, the annual COVID-19 vaccine production will exceed 100 million finished doses annually.
Meanwhile, all doses would exclusively be distributed within the AU's 55 member States and Biovac expects the facility will be brought into the Pfizer-BioNTech supply chain by the end of 2021.
"We are thrilled to collaborate with
Makhoana said it was a critical step forward in strengthening sustainable access to a vaccine in the fight against the worldwide pandemic.
"We believe this collaboration will create an opportunity to more broadly distribute vaccine doses to people in harder-to-reach communities, especially those on the African continent."
Meanwhile, the
"Our latest collaboration with Biovac is a shining example of the tireless work being done, in this instance, to benefit
CEO and Co-founder of
Sahin said
"This is why we will continue to evaluate sustainable approaches that will support the development and production of mRNA vaccines on the African continent."
According to the statement, this latest technology transfer agreement strengthens the already existing relationship and enables Biovac to widen its existing footprint in
Copyright SAnews.gov.za. Distributed by AllAfrica Global Media (allAfrica.com)., source